Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AOB’s OTCs flat after Rx switch

This article was originally published in The Tan Sheet

Executive Summary

Revenues from American Oriental Bioengineering's OTC business were essentially flat at $18.5 million during its fiscal 2009 first quarter, reflecting the switch in China of Jinji Capsule botanical products from OTC to Rx status, the firm says during a May 11 earnings call. The company's OTC business would have grown 16 percent in the quarter ended March 31 if it included Jinji Capsule botanicals, AOB says, noting it switched Jinji Capsules, intended to treat annexitis and pelvic inflammation, to increase sales to China's health care and hospital system. Shenzhen, China- and New York-based AOB reported first-quarter revenue increased 29 percent to $46.1 million, including $8.9 million in net nutraceutical sales. The firm attributed the increase to "continued demand for peptide products and an expanded distribution network," though AOB is deemphasizing nutraceuticals in favor of pharmaceuticals (1"The Tan Sheet" March 16, 2009, p. 13)

Related Content

Topics

UsernamePublicRestriction

Register

PS102932

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel